vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Doximity, Inc.（DOCS）财务数据对比。点击上方公司名可切换其他公司
Doximity, Inc.的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.2倍（$185.1M vs $156.4M），Doximity, Inc.同比增速更快（9.8% vs 7.5%），过去两年Doximity, Inc.的营收复合增速更高（25.2% vs 19.6%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Doximity Inc成立于2010年，是面向医疗专业人士的线上社交服务平台，为平台会员提供精选医疗资讯、远程医疗工具，以及病例协作相关功能，助力医疗从业者高效交流信息、开展诊疗相关工作。
BCRX vs DOCS — 直观对比
营收规模更大
DOCS
是对方的1.2倍
$156.4M
营收增速更快
DOCS
高出2.3%
7.5%
两年增速更快
DOCS
近两年复合增速
19.6%
损益表 — Q1 FY2026 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $156.4M | $185.1M |
| 净利润 | — | $61.6M |
| 毛利率 | — | 89.9% |
| 营业利润率 | 13.6% | 38.9% |
| 净利率 | — | 33.3% |
| 营收同比 | 7.5% | 9.8% |
| 净利润同比 | — | -18.1% |
| 每股收益（稀释后） | $0.00 | $0.31 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXDOCS
| Q1 26 | $156.4M | — | ||
| Q4 25 | $406.6M | $185.1M | ||
| Q3 25 | $159.4M | $168.5M | ||
| Q2 25 | $163.4M | $145.9M | ||
| Q1 25 | $145.5M | $138.3M | ||
| Q4 24 | $131.5M | $168.6M | ||
| Q3 24 | $117.1M | $136.8M | ||
| Q2 24 | $109.3M | $126.7M |
净利润BCRXDOCS
| Q1 26 | — | — | ||
| Q4 25 | $245.8M | $61.6M | ||
| Q3 25 | $12.9M | $62.1M | ||
| Q2 25 | $5.1M | $53.3M | ||
| Q1 25 | $32.0K | $62.5M | ||
| Q4 24 | $-26.8M | $75.2M | ||
| Q3 24 | $-14.0M | $44.2M | ||
| Q2 24 | $-12.7M | $41.4M |
毛利率BCRXDOCS
| Q1 26 | — | — | ||
| Q4 25 | 97.7% | 89.9% | ||
| Q3 25 | 98.6% | 90.3% | ||
| Q2 25 | 98.3% | 89.2% | ||
| Q1 25 | 96.9% | 89.5% | ||
| Q4 24 | 95.4% | 91.6% | ||
| Q3 24 | 97.3% | 90.0% | ||
| Q2 24 | 98.4% | 89.3% |
营业利润率BCRXDOCS
| Q1 26 | 13.6% | — | ||
| Q4 25 | 64.0% | 38.9% | ||
| Q3 25 | 18.6% | 37.8% | ||
| Q2 25 | 18.2% | 37.4% | ||
| Q1 25 | 14.6% | 35.2% | ||
| Q4 24 | -3.4% | 47.4% | ||
| Q3 24 | 6.6% | 38.8% | ||
| Q2 24 | 8.0% | 36.4% |
净利率BCRXDOCS
| Q1 26 | — | — | ||
| Q4 25 | 60.5% | 33.3% | ||
| Q3 25 | 8.1% | 36.8% | ||
| Q2 25 | 3.1% | 36.5% | ||
| Q1 25 | 0.0% | 45.2% | ||
| Q4 24 | -20.4% | 44.6% | ||
| Q3 24 | -12.0% | 32.3% | ||
| Q2 24 | -11.6% | 32.7% |
每股收益（稀释后）BCRXDOCS
| Q1 26 | $0.00 | — | ||
| Q4 25 | $1.13 | $0.31 | ||
| Q3 25 | $0.06 | $0.31 | ||
| Q2 25 | $0.02 | $0.27 | ||
| Q1 25 | $0.00 | $0.31 | ||
| Q4 24 | $-0.13 | $0.37 | ||
| Q3 24 | $-0.07 | $0.22 | ||
| Q2 24 | $-0.06 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $259.0M | $64.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | — | $979.3M |
| 总资产 | $465.1M | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXDOCS
| Q1 26 | $259.0M | — | ||
| Q4 25 | $274.7M | $64.8M | ||
| Q3 25 | $212.9M | $169.2M | ||
| Q2 25 | $260.0M | $137.3M | ||
| Q1 25 | $295.1M | $209.6M | ||
| Q4 24 | $320.9M | $165.3M | ||
| Q3 24 | $96.8M | $184.2M | ||
| Q2 24 | $78.4M | $111.4M |
股东权益BCRXDOCS
| Q1 26 | — | — | ||
| Q4 25 | $-119.2M | $979.3M | ||
| Q3 25 | $-387.9M | $1.1B | ||
| Q2 25 | $-421.6M | $1.0B | ||
| Q1 25 | $-451.9M | $1.1B | ||
| Q4 24 | $-475.9M | $1.0B | ||
| Q3 24 | $-468.6M | $961.2M | ||
| Q2 24 | $-475.6M | $913.6M |
总资产BCRXDOCS
| Q1 26 | $465.1M | — | ||
| Q4 25 | $514.2M | $1.2B | ||
| Q3 25 | $446.4M | $1.3B | ||
| Q2 25 | $457.2M | $1.2B | ||
| Q1 25 | $480.0M | $1.3B | ||
| Q4 24 | $490.4M | $1.2B | ||
| Q3 24 | $491.3M | $1.1B | ||
| Q2 24 | $472.4M | $1.1B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $60.9M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 0.99× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BCRXDOCS
| Q1 26 | — | — | ||
| Q4 25 | $292.0M | $60.9M | ||
| Q3 25 | $41.6M | $93.9M | ||
| Q2 25 | $41.3M | $62.1M | ||
| Q1 25 | $-27.5M | $98.5M | ||
| Q4 24 | $-5.2M | $65.2M | ||
| Q3 24 | $8.2M | $68.3M | ||
| Q2 24 | $-1.4M | $41.2M |
自由现金流BCRXDOCS
| Q1 26 | — | — | ||
| Q4 25 | $291.2M | — | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | — |
自由现金流率BCRXDOCS
| Q1 26 | — | — | ||
| Q4 25 | 71.6% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | — |
资本支出强度BCRXDOCS
| Q1 26 | — | — | ||
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | 0.0% | ||
| Q4 24 | 0.5% | 0.0% | ||
| Q3 24 | 0.1% | 0.0% | ||
| Q2 24 | 0.1% | 0.0% |
现金转化率BCRXDOCS
| Q1 26 | — | — | ||
| Q4 25 | 1.19× | 0.99× | ||
| Q3 25 | 3.23× | 1.51× | ||
| Q2 25 | 8.12× | 1.16× | ||
| Q1 25 | -859.91× | 1.58× | ||
| Q4 24 | — | 0.87× | ||
| Q3 24 | — | 1.55× | ||
| Q2 24 | — | 1.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
DOCS
| Subscription | $175.4M | 95% |
| Service Other | $9.7M | 5% |
